Company intelligence / Profile preview
Novelwise Pharmaceutical Corporation
San Diego, California, United Statesnovelwisepharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
NBM-BMX received USFDA approval on January 4th, 2023 to proceed in Phase Ib/II clinical trials for newly diagnosed glioblastoma multiforme (GBM). The company also has a product called SugarBless for blood sugar control using prenylflavanone compounds.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Small moleculesPrenylflavanone compounds
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Novelwise Pharmaceutical Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novelwise Pharmaceutical Corporation.